Log in to save to my catalogue

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_24cf071741ce4d09aa89b3a6aab76cd5

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer

About this item

Full title

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer

Publisher

London: Nature Publishing Group UK

Journal title

Nature communications, 2016-12, Vol.7 (1), p.13665-13665, Article 13665

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Blockade of the epidermal growth factor receptor (EGFR) with the monoclonal antibodies cetuximab or panitumumab is effective in a subset of colorectal cancers (CRCs), but the emergence of resistance limits the efficacy of these therapeutic agents. At relapse, the majority of patients develop
RAS
mutations, while a subset acquires
EGFR
e...

Alternative Titles

Full title

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_24cf071741ce4d09aa89b3a6aab76cd5

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_24cf071741ce4d09aa89b3a6aab76cd5

Other Identifiers

ISSN

2041-1723

E-ISSN

2041-1723

DOI

10.1038/ncomms13665

How to access this item